Slovakia’s WTP Thresholds for Drug Reimbursement Evaluations - An Uncertain Future for Innovation
Summary
The analyst takes a detailed look at the changing willingness-to-pay (WTP) thresholds for drug reimbursement evaluations in Slovakia, in the midst of regulatory uncertainty following the withdrawal of a proposed draft decree in May 2025, which would have drastically worsened the prospects for new innovative therapies in the country.Table of Contents
- Key findings
- WTP thresholds - a major change in 2022
- December draft decree is a potential compromise solution
- The industry perspective - Why do the thresholds matter?
- Audit office report questions MoH adherence to WTP thresholds
- Outlook and implications
- Disclaimer
